Progyny (PGNY) Bank of America Global Healthcare Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Bank of America Global Healthcare Conference 2026 summary
13 May, 2026Business momentum and market trends
Pipeline and deal size are both stronger than the prior year, with early client commitments and increased RFP activity indicating robust demand.
Industry growth is driven by macro trends such as declining fertility rates and delayed family building, with the fertility market growing at a 9–10% CAGR.
99% client retention and positive client outcomes, including improved pregnancy rates and reduced NICU stays, reinforce value proposition.
Health plan partnerships, such as with Cigna and regional Blues, are deepening and expected to add incremental value and lives.
Two largest clients up for renewal have already committed to stay, with discussions underway for expanded product offerings.
Product and distribution expansion
Progyny Select targets small businesses, with distribution partners signed and meaningful pull-through expected in late Q4.
No direct standalone supplemental plan competition for Progyny Select outside of mandated states.
New products in menopause, postpartum, leave, and benefit navigation are resonating, with 20% of current and 40% of new clients adding these benefits.
Investments in digital assets and global product suite aim to match U.S. offerings for multinational clients.
Utilization, guidance, and financial strategy
Utilization rates remain consistent and at the higher end of guidance, supporting a strong outlook for the year.
Guidance philosophy incorporates current trends and allows for variability, with current activity skewing toward the high end.
Platform investments focus on efficiency, interoperability, and AI to enhance care management and member experience.
ROI strategy centers on empowering care advocates and avoiding future hiring as the business scales.
M&A remains focused on small, accretive tuck-in deals; excess cash may be returned to shareholders via buybacks.
Latest events from Progyny
- Q1 revenue up 12.2% (ex-large client), net income up 61%, and 8.8M shares repurchased.PGNY
Q1 20268 May 2026 - Proxy covers director elections, auditor ratification, pay reforms, and governance changes.PGNY
Proxy filing10 Apr 2026 - Votes will address director elections, auditor ratification, and governance amendments.PGNY
Proxy filing10 Apr 2026 - Key votes include director elections, auditor ratification, and reducing supermajority voting thresholds.PGNY
Proxy filing31 Mar 2026 - Strong utilization and new product launches drive growth amid stable competition and tech investment.PGNY
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026 - Stable growth, high retention, and new market expansion drive a positive long-term outlook.PGNY
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Record 2025 revenue and margin gains, with 2026 guidance projecting further growth.PGNY
Q4 202526 Feb 2026 - Q2 revenue up 9%, guidance cut 5%, with record margins and $100M added to share buybacks.PGNY
Q2 20242 Feb 2026 - Targets $2.4B+ revenue and 20% CAGR by 2028, fueled by new women's health products.PGNY
Investor Day 20242 Feb 2026